For many Type-1 diabetes patients and the health plans that cover them, the cost of insulin is a burdensome problem. And amidst a global supply chain crisis, access to insulin has only compounded the issue.   San Diego-based rBIO looks to solve both problems with a novel approach to manufacturing the drug.